Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non Operating Income (2018 - 2025)

X4 Pharmaceuticals' Other Non Operating Income history spans 8 years, with the latest figure at -$676000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 399.12% year-over-year to -$676000.0; the TTM value through Dec 2025 reached -$1.1 million, up 91.19%, while the annual FY2025 figure was -$753000.0, 326.81% down from the prior year.
  • Other Non Operating Income reached -$676000.0 in Q3 2025 per XFOR's latest filing, down from -$547000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $25.2 million in Q3 2023 to a low of -$13.8 million in Q1 2024.
  • Average Other Non Operating Income over 5 years is $700000.0, with a median of $60000.0 recorded in 2022.
  • Peak YoY movement for Other Non Operating Income: surged 5806.12% in 2023, then crashed 11282.93% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$689000.0 in 2021, then plummeted by 445.28% to -$3.8 million in 2022, then skyrocketed by 268.51% to $6.3 million in 2023, then plummeted by 88.94% to $700000.0 in 2024, then crashed by 196.57% to -$676000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Other Non Operating Income are -$676000.0 (Q3 2025), -$547000.0 (Q2 2025), and $105000.0 (Q1 2025).